Selected Publications

Academic Article

Year Title Altmetric
2019 The BET inhibitor JQ1 attenuates double-strand break repair and sensitizes models of pancreatic ductal adenocarcinoma to PARP inhibitors 2019
2018 FTY720 enhances the anti-tumor activity of carboplatin and tamoxifen in a patient-derived xenograft model of ovarian cancer 2018
2018 Targeting PIM kinase as a therapeutic strategy in human hepatoblastoma 2018
2018 Pediatric anaplastic embryonal rhabdomyosarcoma: Targeted therapy guided by genetic analysis and a patient-derived xenograft study 2018
2018 JQ1 induces DNA damage and apoptosis, and inhibits tumor growth in a patient-derived xenograft model of cholangiocarcinoma 2018
2017 Whole exome sequencing identified sixty-five coding mutations in four neuroblastoma tumors 2017
2016 The tumor-associated glycosyltransferase ST6Gal-I regulates stem cell transcription factors and confers a cancer stem cell phenotype 2016
2016 The BET bromodomain inhibitor JQ1 suppresses growth of pancreatic ductal adenocarcinoma in patient-derived xenograft models 2016
2016 Dysregulated human Tyrosyl-DNA phosphodiesterase I acts as cellular toxin 2016
2015 ICAM-2 confers a non-metastatic phenotype in neuroblastoma cells by interaction with α-actinin 2015
2015 The role of ICAM-2 in neuroblastoma 2015
2013 Development and Histopathological Characterization of Tumorgraft Models of Pancreatic Ductal Adenocarcinoma 2013
2013 N-glycosylation of ICAM-2 is required for ICAM-2-mediated complete suppression of metastatic potential of SK-N-AS neuroblastoma cells 2013
2009 Cell adhesion molecules as targets for therapy of neuroblastoma. 2009
2008 ICAM-2 expression mediates a membrane-actin link, confers a nonmetastatic phenotype and reflects favorable tumor stage or histology in neuroblastoma 2008
2007 Tumor-targeted enzyme/prodrug therapy mediates long-term disease-free survival of mice bearing disseminated neuroblastoma 2007
2006 Development of a tumor-selective approach to treat metastatic cancer 2006
2006 Development of an etoposide prodrug for dual prodrug-enzyme antitumor therapy. 2006
2005 Inhibition of acetylcholinesterase by the anticancer prodrug CPT-11. 2005
2005 Inhibition of carboxylesterases by benzil (diphenylethane-1,2-dione) and heterocyclic analogues is dependent upon the aromaticity of the ring and the flexibility of the dione moiety. 2005
2005 The crystal structure of the complex of the anticancer prodrug 7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxycamptothecin (CPT-11) with Torpedo californica acetylcholinesterase provides a molecular explanation for its cholinergic action. 2005
2005 Development of prodrugs for enzyme-mediated, tumor-selective therapy. 2005
2004 Characterization of inhibitors of specific carboxylesterases: development of carboxylesterase inhibitors for translational application. 2004
2003 Activation of a camptothecin prodrug by specific carboxylesterases as predicted by quantitative structure-activity relationship and molecular docking studies. 2003
2003 Synthesis and evaluation of esters and carbamates to identify critical functional groups for esterase-specific metabolism 2003

Full Name

  • Karina Yoon